News | July 02, 2025
Cadila Pharmaceuticals launches Bilacad Dex Syrup
A triple-action Formula for comprehensive respiratory relief
A triple-action Formula for comprehensive respiratory relief
EBITDA before special items decreases to €4.08 billion (7.4%)
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Subscribe To Our Newsletter & Stay Updated
